IMP welcomes European Commission approval of KYGEVVI® for TK2d
European Commission approves KYGEVVI® for TK2d IMP warmly welcomes the decision by the European Commission to approve KYGEVVI® (doxecitine and doxribtimine) as […]
European Commission approves KYGEVVI® for TK2d IMP warmly welcomes the decision by the European Commission to approve KYGEVVI® (doxecitine and doxribtimine) as […]
New MELAS Consensus: A Critical Resource for Doctors and Patients Worldwide In November 2025, leading international experts gathered in Pisa,
International MELAS Consensus Meeting in Pisa: A Milestone for Patient Advocacy and Research From 28 to 30 November this autumn,